Suven Life Sciences posts Q4 loss of ₹45.6 crore as R&D expenses stay elevated
Sarthak Kumar
Suven Life Sciences Ltd reported a consolidated net loss of ₹45.6 crore for the quarter ended March 2026, compared to a loss of ₹43.9 crore in the corresponding quarter last year, as research and development spending remained elevated.
The company’s revenue for Q4FY26 rose sharply to ₹8.3 crore from ₹2.7 crore in Q4FY25.
However, operational expenses continued to weigh on profitability. Total expenses during the quarter stood at ₹53.9 crore compared to ₹46.6 crore a year ago. Research & development and operational expenses alone came in at ₹52.2 crore for the quarter.
Depreciation and amortisation expenses stood at ₹1.6 crore, while finance costs were marginal at ₹0.2 crore during the March quarter.
The company reported a total comprehensive loss of ₹46.1 crore for Q4FY26 compared to a comprehensive loss of ₹44.5 crore in the corresponding period last year.
For the full financial year FY26, Suven Life Sciences reported revenue of ₹21 crore compared to ₹17.6 crore in FY25. The annual net loss widened to ₹276.3 crore from ₹160.7 crore in the previous year.
Total expenses for FY26 stood at ₹297.4 crore compared to ₹178.3 crore in FY25, reflecting continued investments in drug discovery and clinical development programmes.
Along with the results, the company also shared updates on its CNS-focused clinical pipeline.
Suven said its Alzheimer’s drug candidate SUVN-502 has achieved the 76% enrolment milestone in its global Phase 3 clinical trial. The company expects patient enrolment to conclude by the end of calendar year 2026, potentially enabling data readout during Q2-Q3 of calendar year 2027.
The company further stated that:
SUVN-G3031 entered global Phase 3 trials for episodic narcolepsy treatment in April 2026.
SUVN-911 completed a Phase 2B study in the US, with data expected shortly.
SUVN-D4010 received FDA IND approval for a Phase 2 proof-of-concept study in major depressive disorder-related cognitive dysfunction.
SUVN-I6107 completed Phase 1 safety studies and is preparing for Phase 2 clinical trials.
Suven Life Sciences continues to focus on CNS drug discovery and development while maintaining aggressive R&D investments across multiple clinical programmes.
Disclaimer: This article is for informational purposes only and should not be construed as investment advice.